SynthesisTumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine2016
CD20-negative diffuse large B cell lymphoma: a comprehensive analysis of 695 cases.
Synthesis in Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 30 citations in OpenAlex.
- ALK-positive, EBV-positive Large B-cell lymphoma in an HIV patient: a diagnostic pitfall mimicking plasmablastic lymphoma.Journal of hematopathology · 2026Article
- Multifunctional CD38 in the pathogenesis and treatment of B-cell lymphomas.American journal of blood research · 2026Review
- First-line treatment with polatuzumab vedotin improves efficacy and survival in newly diagnosed patients with advanced diffuse large B-cell lymphoma: a multicentre retrospective analysis.Annals of medicine · 2025Article
- Polatuzumab vedotin and bendamustine (Pola-B) was effective for refractory CD20-negative double-expressor lymphoma.Annals of hematology · 2025Article
- A rare case of CD20JAAD case reports · 2024Article
- Double-hit primary central nervous system lymphoma with histogenetically proven bone marrow infiltration: a case report and a review of the literature.Brain tumor pathology · 2024Review
- ALK-positive large B-cell lymphoma (ALK + LBCL) with aberrant CD3 expression.Journal of hematopathology · 2024Article
- A rare case of an extra-oral plasmablastic lymphoma presenting through a scrotal abscess in a 42-year-old man.Annals of the Royal College of Surgeons of England · 2024Article
- Primary central nervous system CD20-negative diffuse large B-cell lymphoma: a case report.BMC neurology · 2022Article
- Extranodal Involvement of the Anorectal Region in an HIV-Positive Patient With Plasmablastic Lymphoma: A Case Report.Cureus · 2022Article
- Plasmablastic Lymphoma of the Endometrium: A Rare Site for Primary Presentation.Journal of obstetrics and gynaecology of India · 2022Article
- Case report of primary CD20 negative diffuse large B-cell lymphoma.Oxford medical case reports · 2021Article
- CD-20 Negative Plasmablastic Lymphoma Lurking in the Shadow of a Leiomyoma - Diagnosis and Management.Cureus · 2019Article
- Article
- Plasmablastic lymphoma: current perspectives.Blood and lymphatic cancer : targets and therapy · 2018Review
- HHV8/KSHV-Positive Lymphoproliferative Disorders and the Spectrum of Plasmablastic and Plasma Cell Neoplasms: 2015 SH/EAHP Workshop Report-Part 3.American journal of clinical pathology · 2017Article
- Genetic and Epigenetic Modulation of CD20 Expression in B-Cell Malignancies: Molecular Mechanisms and Significance to Rituximab Resistance.Journal of clinical and experimental hematopathology : JCEH · 2016Article
- Primary Nodal Unclassifiable CD20 Negative Diffuse Large B-cell Lymphoma With DualClinical pathology (Thousand Oaks, Ventura County, Calif.)Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
CD20 expression is absent in a variety of diffuse large B cell lymphomas (DLBCLs), including plasmablastic lymphoma, primary effusion lymphoma, anaplastic lymphoma, kinase-positive DLBCL, and large B cell lymphoma arising in human herpesvirus 8-associated multicentric Castleman disease. These rare and heterogeneous tumors are characterized by the presence of proliferating immunoblasts with similar transcriptional profiles as those of plasma cells and are typically associated with highly aggressive pathologies, with high levels of chemotherapy resistance and low survival rates; thus, they pose significant diagnostic and treatment challenges. We conducted a systematic literature review of the limited existing clinical data to summarize the current knowledge regarding the biological basis, diagnostic limits, and potential therapeutic targets of distinct variants of CD20-negative DLBCL. This review will hopefully increase the awareness of these rare disorders among clinicians and pathologists and prompt basic and clinical research.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.